Prescriber Scope of Practice for General Psychiatry in Georgia

If you’re a psychiatrist, PMHNP, or prescriber wondering whether you can still prescribe controlled substances via telehealth — or worried about what happens when the temporary rules expire — you’re not alone. After years of policy whiplash, here’s where we actually stand in early 2026.

The short answer: Yes, you can prescribe controlled substances via telehealth through at least December 31, 2026, thanks to the fourth federal extension announced by HHS and the DEA in January 2026. But the rules are changing, and what’s legal in your state matters just as much as federal policy.

Let’s cut through the confusion and talk about what you need to know to practice compliantly — and profitably.

The Current Federal Rules (Through End of 2026)

As of February 2026, psychiatrists and psychiatric nurse practitioners can prescribe Schedule II–V controlled substances via telehealth without requiring an initial in-person exam. This includes:

• Stimulants (Adderall, Ritalin) for ADHD
• Benzodiazepines (Xanax, Klonopin) for anxiety disorders
• Buprenorphine for opioid use disorder
• Other psychiatric medications in Schedules III–V

This flexibility stems from COVID-era emergency waivers that have been repeatedly extended. The most recent extension runs through December 31, 2026, giving providers clarity while the DEA finalizes permanent rules.

What you need to do:

• Conduct a proper evaluation via real-time audio-video (telephone-only generally doesn’t qualify, except for buprenorphine in some cases)
• Document the clinical encounter thoroughly
• Follow your state’s PDMP (Prescription Drug Monitoring Program) requirements
• Use e-prescribing (required in most states for controlled substances)
• Maintain standard of care — just because it’s legal doesn’t mean every patient is appropriate for telehealth-only treatment

The Ryan Haight Act — the 2008 law that normally requires at least one in-person visit before prescribing controlled substances online — remains suspended under these emergency flexibilities.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: The DEA’s Proposed Permanent Rules

In January 2025, the DEA proposed three new rules to replace the temporary extensions. While these aren’t final yet, they signal where telehealth prescribing is headed:

1. Special Telemedicine Registration for Prescribers

The DEA wants to create a ‘Special Telemedicine Prescriber Registration’ that would allow qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam.

For Schedule II substances (stimulants, short-acting opioids), this special registration would initially be limited to:

• Board-certified psychiatrists
• Hospice and palliative care physicians
• Long-term care facility physicians
• Pediatricians (for specific conditions)

For Schedule III–V, any qualified prescriber could apply.

What this means for you: If you’re a board-certified psychiatrist, you’d be able to continue prescribing ADHD medications, for example, via telehealth indefinitely once you obtain this registration. PMHNPs might face more restrictions depending on how the final rule defines ‘qualified specialist.’

The rule would also require telehealth platforms to register with the DEA for the first time — a response to high-profile cases of over-prescribing by some online services.

2. Buprenorphine Pathway (6 Months Audio-Only)

For opioid use disorder treatment, providers could initiate buprenorphine via telehealth (including audio-only phone calls) and continue treatment for up to 6 months before an in-person evaluation is required.

This is more permissive than current law and recognizes that telehealth has dramatically improved addiction treatment access. After the initial 6 months, patients would need at least one in-person visit to continue.

3. National PDMP and Platform Accountability

The proposed rules would establish a national Prescription Drug Monitoring Program to track controlled substance prescriptions across state lines, and require online platforms to report prescribing data to regulators.

Reality check: These rules are still being finalized. Public comment periods have closed, but implementation likely won’t happen until late 2026 or 2027. Until then, the temporary extension remains in effect.

State-by-State: Where the Real Complexity Lives

Federal law sets the floor, but states can (and do) impose stricter requirements. Here’s what you need to know in the six highest-volume telehealth states:

California: Open and Getting More So

The rules:

• No state-level restrictions beyond federal law for telehealth prescribing
• Must check CURES (California’s PDMP) before first Schedule II–IV prescription and every 4 months during ongoing treatment
• 100% e-prescribing required since 2022
• Standard of care applies — video visit can fully establish patient relationship

NP scope: California is phasing in full practice authority for experienced PMHNPs. As of 2024-2026, NPs with 3+ years in supervised practice can operate independently. By 2026, they can open their own practices without physician oversight.

Bottom line: California is telehealth-friendly. If you’re licensed in CA and follow PDMP and e-prescribing rules, you’re good to go.

Texas: Physician-Friendly, NP-Limited

The rules:

• Real-time video required to establish patient relationship
• Cannot prescribe controlled substances for chronic pain via telehealth (without prior in-person visit)
• Must check Texas PMP before prescribing opioids, benzos, barbiturates

NP scope: This is where Texas gets restrictive. PMHNPs and PAs cannot prescribe Schedule II controlled substances in outpatient settings. Period. Schedule II authority is limited to hospital admissions (≥24 hours), emergency departments, or hospice care.

What this means: If you’re running a telehealth practice treating ADHD in Texas, you need a psychiatrist (MD/DO) on staff. NPs can handle most anxiety and depression medications (Schedule III–V), but any patient needing Adderall or Vyvanse must see a physician.

Bottom line: Texas works great for psychiatrists. For NPs, you’ll need physician collaboration and can’t touch stimulants in outpatient care.

Florida: The Psychiatric Exception State

The rules:

• Out-of-state providers can register for a special Florida telehealth license (unique among states)
• Schedule II controlled substances cannot be prescribed via telehealth — with four exceptions:

1. Psychiatric treatment (this is you!)
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

• Schedules III–V allowed via telehealth with standard of care
• Must check E-FORCSE (Florida PDMP) before prescribing any controlled substance

NP scope: Florida PMHNPs must practice under physician supervision (no independent practice for psychiatric specialty). Primary care NPs can get autonomy in Florida, but not psych NPs.

Bottom line: Florida explicitly allows psychiatrists to prescribe stimulants and other Schedule II meds for mental health conditions via telehealth. The psychiatric carve-out is your friend here. Just document that you’re treating a psychiatric disorder, not using stimulants off-label.

New York: Progressive and PDMP-Strict

The rules:

• No in-person requirement for telehealth prescribing
• Must check I-STOP (NY’s PDMP) before every Schedule II, III, or IV prescription — one of the strictest PDMP mandates in the country
• 100% e-prescribing required since 2016 (first state to mandate it)
• Audio-only telehealth allowed for some mental health services (reimbursable by Medicaid)

NP scope: PMHNPs with >3,600 clinical hours can practice fully independently. Below that threshold, they need a collaborative agreement.

Bottom line: New York is telehealth-friendly and NP-progressive, but the PDMP checking requirement is non-negotiable. Build it into your workflow for every controlled prescription.

Pennsylvania: Follow Standard of Care

The rules:

• No comprehensive telehealth statute (yet — multiple bills have stalled)
• Boards allow telehealth under general practice authority
• Must check PA PMP before prescribing opioids or benzos
• E-prescribing required for controlled substances

NP scope: PMHNPs need collaborative agreements with physicians (actually two physicians for full prescriptive authority). Can prescribe Schedule II for up to 30 days, Schedule III–IV up to 90 days with proper collaboration.

Bottom line: Pennsylvania is in regulatory limbo — telehealth is permitted but not codified. Follow the same standard of care you would in-person, document thoroughly, and ensure your NPs have proper collaborative agreements.

Illinois: Full Practice Available (With Strings)

The rules:

• Telehealth recognized under standard of care
• Must check Illinois PMP before prescribing opioids (encouraged for all controlled substances)
• E-prescribing required for all controlled substances since 2023

NP scope: PMHNPs can obtain Full Practice Authority after 4,000 hours and additional training. However, even with FPA, Illinois requires NPs to have a physician consultation arrangement for continuous Schedule II opioid or benzodiazepine prescribing (limited to 30-day supplies without consult).

Bottom line: Illinois offers NP independence, but with guardrails on high-risk medications. Stimulants for ADHD may fall under similar consultation requirements — verify with the state nursing board.

Psychiatrist vs PMHNP: Authority Differences That Matter

Psychiatrists (MD/DO) have the same prescribing authority in every state — full independent practice, all schedules of controlled substances. Your only limits are federal DEA rules and state-specific telehealth requirements.

Psychiatric Nurse Practitioners face a patchwork:

For telehealth platforms: If you’re recruiting PMHNPs, you need to know their state’s rules cold. An NP in New York can run a full telepsychiatry practice independently. That same NP in Texas would need a supervising physician and couldn’t prescribe stimulants at all in outpatient settings.

Compliance Essentials Every Provider Needs

Regardless of state, here’s your baseline compliance checklist:

1. PDMP Checks

Every state with a PDMP (which is all 50 now) requires checking it before prescribing controlled substances. Requirements vary:

• California: Check before first Rx and every 4 months ongoing
• New York: Check every single time before prescribing Schedule II–IV
• Texas: Check before prescribing opioids, benzos, barbiturates
• Florida: Check before prescribing any controlled substance for patients ≥16

2. E-Prescribing

Most states now require electronic prescribing for controlled substances (EPCS). Paper prescriptions for Schedule II–V are prohibited in:

• California (since 2022)
• New York (since 2016)
• Texas (with narrow exceptions)
• Illinois (since 2023)

Your telehealth platform should have EPCS capability built-in with two-factor authentication.

3. DEA Registration & Training

• You need a DEA registration in every state where your patients are located
• As of 2023, all DEA registrants must complete 8 hours of training on substance use disorders and appropriate prescribing (one-time requirement, but checked at renewal)
• The old ‘X-waiver’ for buprenorphine was eliminated in 2023 — any DEA-registered provider can now prescribe buprenorphine for OUD without additional certification

4. Documentation Standards

Document as if you’re going to be audited (because you might be). Your telehealth notes should include:

• Thorough history and mental status exam
• Clear indication for any controlled substance prescribed
• PDMP review and findings
• Discussion of risks, benefits, alternatives
• Treatment plan and follow-up schedule
• For states like Florida, explicitly note that Schedule II prescriptions are for psychiatric indications

5. State Licensure

You must be licensed in the state where the patient is physically located during the visit. A few options:

• Individual state licenses (time-consuming but comprehensive)
• Interstate Medical Licensure Compact (IMLC) — 40 states participate, streamlines getting multiple licenses for physicians
• Special state telehealth registrations — only a few states offer these (Florida being the main one)

The Nurse Licensure Compact exists for RNs but not for APRNs/NPs. PMHNPs need individual state licenses or must go through each state’s APRN licensing process.

The Economics: Why Platforms Win Over DIY Marketing

Let’s talk business reality. Many psychiatrists and PMHNPs consider building their own telehealth practice and handling patient acquisition themselves. Here’s why that’s usually a money-losing proposition:

The real cost of DIY patient acquisition:

Most providers drastically underestimate what it costs to acquire a qualified psychiatric patient. Let’s break it down:

• SEO: Takes 6–12 months of consistent investment ($2,000–5,000/month to an agency or consultant) before you start seeing meaningful organic traffic. Most solo providers don’t have the patience or expertise.

• Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert. A realistic cost per booked patient through PPC is $200–400+ after you factor in wasted clicks, consultation time for tire-kickers, and no-shows from cold leads.

• Directory Listings: Psychology Today and Zocdoc charge monthly fees ($29.99–$59/month) and you compete with hundreds of other providers on the same page. Zocdoc adds a per-booking fee ($35–100 depending on specialty and market). Your total monthly cost adds up fast, and you’re still doing all the work of qualification and scheduling.

• Hidden costs: Staff time to handle and qualify leads, tech stack for telehealth (EMR, scheduling, payments, video platform), failed campaigns you abandon after burning through ad spend, opportunity cost of time spent marketing instead of seeing patients.

Realistic all-in patient acquisition cost through DIY marketing: $200–500+ per patient when you factor in everything.

And that’s assuming you eventually figure it out. Many providers spend $3,000–5,000/month for 6+ months with minimal results before giving up.

The platform model:

Klarity Health and similar telehealth platforms use a pay-per-appointment model. You pay a standard listing fee for each new patient lead that books with you. Key advantages:

✅ No upfront marketing spend — Zero risk. You don’t pay until you actually see a patient.

✅ Pre-qualified patients — Patients are already matched to your specialty, insurance acceptance, and availability. No time wasted on calls with people who can’t afford your services or aren’t appropriate for telehealth.

✅ No wasted ad spend — You’re not gambling $5,000/month on Google Ads hoping something sticks.

✅ Built-in infrastructure — Telehealth platform, EMR integration, scheduling, payment processing, compliance support all included. No separate platform costs.

✅ Both insurance and cash-pay patients — Diversified revenue stream.

✅ You control your schedule — Set your availability, accept the patients you want, and only pay when you see them.

Frame it this way: Instead of spending $3,000–5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you. That’s guaranteed ROI versus gambling on marketing channels you may not understand.

For providers starting out or scaling their practice, platforms remove the risk entirely. Even established providers often find that platform-acquired patients are more cost-effective than their DIY channels once you honestly account for all costs.

FAQ: What Providers Actually Ask

Can I prescribe Adderall via telehealth in 2026?

Yes, through at least December 31, 2026, under the federal extension. After that, it depends on whether the DEA finalizes the Special Telemedicine Registration rule (which would allow board-certified psychiatrists to continue indefinitely). State rules apply — in Texas, for example, NPs cannot prescribe it in outpatient telehealth, but psychiatrists can.

Do I need an in-person visit first before prescribing controlled substances?

Not under current federal rules (through end of 2026). However, check your state law — some states have additional requirements. And clinical judgment matters: some patients should be seen in person even if it’s not legally required.

What if a patient moves to another state mid-treatment?

You need to be licensed in their new state to continue prescribing. If they move temporarily (vacation, visiting family), gray area — but safest practice is to have them established with their regular state address. For ongoing treatment, get licensed in any state where you regularly have patients.

Can I do audio-only (telephone) visits for controlled substance prescribing?

Generally no, except for buprenorphine for OUD (explicitly allowed under current federal guidance). For stimulants, benzos, and other psychiatric meds, use real-time video. Some states allow audio-only for mental health services broadly (like California and New York for follow-ups), but for controlled substances, video is the standard.

What happens if I’m audited by the DEA or state medical board?

They’ll review your documentation. You need to show:

• Proper evaluation before prescribing
• Medical necessity for the controlled substance
• PDMP checks (if state-mandated)
• Ongoing monitoring and follow-up
• No red flags of diversion or over-prescribing

Document thoroughly, use clinical judgment, and when in doubt, require an in-person evaluation.

Do I need malpractice insurance that covers telehealth?

Yes. Most malpractice policies now include telehealth, but verify with your insurer. Also ensure coverage extends to all states where you’re licensed and seeing patients.

What about prescribing for patients with substance use history?

Use extra caution with controlled substances for patients with addiction history. Document your risk-benefit analysis, consider non-controlled alternatives first, use shorter prescription intervals, and monitor PDMP closely. This is where telehealth-only care might not be appropriate — clinical judgment required.

What This Means for Your Practice in 2026

If you’re a psychiatrist, telehealth prescribing is wide open right now and likely to remain so under any finalized DEA rule (you’re explicitly included in the proposed Special Registration). Focus on:

1. Getting licensed in your target states (use IMLC if available)
2. Building PDMP checks into your workflow
3. Ensuring your platform or EMR has compliant EPCS
4. Documenting thoroughly to meet standard of care

If you’re a PMHNP, your path depends heavily on your state:

• Full practice states (NY, CA phasing in, IL with FPA) — You can run a full telepsychiatry practice independently. Just ensure you meet your state’s experience/training requirements.
• Collaborative states (PA) — You need physician agreements but can operate with significant autonomy.
• Restricted states (TX, FL) — You need physician supervision, and may not be able to prescribe certain Schedule II medications at all in outpatient telehealth settings.

For both, the key is staying ahead of the regulatory curve. The DEA’s permanent rules will likely be finalized in late 2026 or 2027. When they drop, you’ll need to adapt quickly — possibly applying for new registrations, adjusting your patient evaluation protocols, or limiting your scope to certain medications.

The Klarity Advantage: Built for Compliance, Built for Growth

This is where working with a platform like Klarity Health makes sense. Rather than spending thousands of dollars monthly on marketing (with uncertain results), dealing with compliance tracking across multiple states, building your own tech stack, and hoping the rules don’t change mid-stream — you join a network that:

• Handles patient acquisition at a predictable cost per patient (you pay only when you see someone)
• Pre-qualifies and matches patients to your specialty, availability, and state licensure
• Provides built-in telehealth infrastructure (video platform, scheduling, EPCS-capable prescribing, HIPAA-compliant documentation)
• Monitors regulatory changes and updates platform compliance so you don’t have to track every DEA press release
• Supports both insurance and cash-pay models, giving you revenue diversification

You control your schedule, you choose which patients to see, and you focus on practicing psychiatry instead of marketing and compliance paperwork.

For new providers: Platforms eliminate the 6–12 month ramp-up period (and the $20,000–50,000 you’d burn getting there) of building a practice from scratch.

For established providers: Platforms offer incremental patient volume without the overhead of hiring marketing staff or agencies.

The business model is simple: only pay when a qualified patient books with you. Compare that to spending $3,000–5,000/month on Google Ads and SEO with no guaranteed patients, and the ROI is obvious.

Bottom line: Telehealth prescribing for psychiatry is alive and well in 2026, but the rules are state-specific and evolving. Understanding federal DEA policy, your state’s telehealth and scope-of-practice laws, and compliance requirements (PDMP, EPCS, documentation standards) isn’t optional — it’s the baseline for practicing legally and safely.

If you’re ready to grow your practice without gambling on expensive, unproven marketing channels, platforms like Klarity Health offer a smarter path: predictable patient acquisition costs, built-in compliance infrastructure, and the freedom to focus on what you do best — treating patients.

Ready to join a provider network that handles the hard stuff so you can focus on patient care? Explore how Klarity Health connects you with pre-qualified patients while managing the regulatory complexity of multi-state telehealth.

Sources & References

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026): www.hhs.gov

2. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Telehealth While Establishing New Patient Protections’ (January 16, 2025): www.dea.gov

3. Florida Statutes §456.47 – Use of Telehealth to Provide Services (2025 Edition): www.leg.state.fl.us

4. Akerman LLP Healthcare Law Bulletin – ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth’ (March 2023): www.akerman.com

5. Texas Medical Board – Prescriptive Authority and Supervision FAQs (Updated 2024): www.tmb.texas.gov

6. SAMHSA – ‘MAT Act Waiver Elimination and Updated Training Requirements’ (2023): www.samhsa.gov

7. Tebra (The Intake) – ‘State-by-State Breakdown of Nurse Practitioner Practice Authority Laws’ (Updated December 4, 2025): www.tebra.com

8. JD Supra / National Law Review – ‘States and Feds Signal Big Changes to Telehealth Prescribing’ (February 2023): www.jdsupra.com

Note: Regulatory guidance is current as of February 2026. Providers should verify current rules with their state medical/nursing boards and monitor DEA announcements for finalized permanent telehealth regulations.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices